Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL

Treatment with the peroxisome proliferator-activated receptor γ agonist rosiglitazone has been reported to increase HDL-cholesterol (HDL-C) levels, although the mechanism responsible for this is unknown. We sought to determine the effect of rosiglitazone on HDL apolipoprotein A-I (apoA-I) and apoA-I...

ver descrição completa

Detalhes bibliográficos

Principais autores:	John S. Millar, Katsunori Ikewaki, LeAnne T. Bloedon, Megan L. Wolfe, Philippe O. Szapary, Daniel J. Rader
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2011-01-01
Colecção:	Journal of Lipid Research
Assuntos:	apolipoprotein A-I stable isotope thiazolidinedione lipoprotein kinetics high density lipoprotein
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S0022227520405048
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!